← Back to patent-cliff list
CAS 1329485-55-3
tert-butyl (R)-(4-(2-(2-aminothiazol-4-yl)acetamido)phenethyl)(2-hydroxy-2-phenylethyl)carbamate
Codes：MIRA-007
Application context (from source-drug indications)
神经性膀胱功能障碍米拉贝隆膀胱过度活动症米拉贝隆
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| 米拉贝隆Mirabegron | Tier B — Position early | 2029 |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(R)-2-phenyloxirane→2-(4-nitrophenyl)ethan-1-amine hydrochloride→(R)-2-((4-nitrophenethyl)amino)-1-phenylethan-1-ol→tert-butyl (R)-(2-hydroxy-2-phenylethyl)(4-nitrophenethyl)carbamate→tert-butyl (R)-(4-aminophenethyl)(2-hydroxy-2-phenylethyl)carbamate→2-(2-aminothiazol-4-yl)acetic acid→tert-butyl (R)-(4-(2-(2-aminothiazol-4-yl)acetamido)phenethyl)(2-hydroxy-2-phenylethyl)carbamate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.